Home / Companies / Results / Eris Lifesciences consolidated Q4 PBT up 5.9% at Rs 62 cr, income rises 9%

Eris Lifesciences consolidated Q4 PBT up 5.9% at Rs 62 cr, income rises 9%

Full-year pre-tax profit up 4.46% at Rs 331.52 cr

The quarterly and annual financial results are to be submitted by listed entities to Sebi within 45 days and 60 days from the end of the quarter and financial year, respectively

Premium

In the fourth quarter of FY20, the company had announced and paid an interim dividend of Rs 2.87 per share, apart from completing buyback of shares worth Rs 100 crore.

Vinay Umarji Ahmedabad

2 min read Last Updated : Jun 02 2020 | 7:28 PM IST

Drug maker Eris Lifesciences Ltd has registered a 5.88 per cent growth in its consolidated profit before tax (PBT) at Rs 61.67 crore for the quarter ended March 31, 2020 as against Rs 58.24 crore in the corresponding period last year.

The company's consolidated total income in Q4 of FY20 increased by 9.3 per cent to stand at Rs 247.81 crore, as compared to Rs 226.55 crore in Q4 of FY19. Consolidated PBT for the full financial year 2019-20 rose by 4.46 per cent to Rs 331.52 crore from Rs 317.36 crore in FY 2018-19. On the other hand, its consolidated

Topics : Coronavirus Lockdown Eris Lifesciences Q4 Results

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in